Evogliptin Tartrate/Metformin Hydrochloride

酒石酸艾格列汀/盐酸二甲双胍

Report date: 2026/04/08 20:02:35

Base Information

Drug NameEvogliptin Tartrate/Metformin Hydrochloride
Drug Alias Name盐酸二甲双胍/酒石酸艾格列汀Metformin Hydrochloride/Evogliptin Tartrateevogliptin + metformin XRSugamet XRDA-1229_01
ClassificationSmall molecules
Mechanisms of ActionDipeptidyl peptidase IV inhibitorsProtein kinase AMP-activated non-catalytic subunit beta 1 activators
TargetsDipeptidyl peptidase IVProtein kinase AMP-activated non-catalytic subunit beta 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2015/12/01
Country/TerritorySouth Korea
CombinationsYes Metformin HydrochlorideEvogliptin Tartrate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesDong-A Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDong-A ST Co LtdDong-A Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeA10BD22
Related LinksN/A